| WHO grade II and III meningiomas: a study of prognostic factors A Durand, F Labrousse, A Jouvet, L Bauchet, M Kalamaridès, P Menei, ... Journal of neuro-oncology 95, 367-375, 2009 | 326 | 2009 |
| High Incidence of Activating TERT Promoter Mutations in Meningiomas Undergoing Malignant Progression S Goutagny, JC Nault, M Mallet, D Henin, JZ Rossi, M Kalamarides Brain pathology 24 (2), 184-189, 2014 | 263 | 2014 |
| Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse M Kalamarides, M Niwa-Kawakita, H Leblois, V Abramowski, ... Genes & development 16 (9), 1060-1065, 2002 | 251 | 2002 |
| Current treatment options for meningioma C Apra, M Peyre, M Kalamarides Expert review of neurotherapeutics 18 (3), 241-249, 2018 | 224 | 2018 |
| Meningiomas and neurofibromatosis S Goutagny, M Kalamarides Journal of neuro-oncology 99, 341-347, 2010 | 171 | 2010 |
| Identification of a progenitor cell of origin capable of generating diverse meningioma histological subtypes M Kalamarides, AO Stemmer-Rachamimov, M Niwa-Kawakita, ... Oncogene 30 (20), 2333-2344, 2011 | 165 | 2011 |
| Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas D Lallemand, J Manent, A Couvelard, A Watilliaux, M Siena, F Chareyre, ... Oncogene 28 (6), 854-865, 2009 | 149 | 2009 |
| Evaluation of the management of postoperative aseptic meningitis V Zarrouk, I Vassor, F Bert, D Bouccara, M Kalamarides, N Bendersky, ... Clinical infectious diseases 44 (12), 1555-1559, 2007 | 136 | 2007 |
| Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2 JO Blakeley, DG Evans, J Adler, D Brackmann, R Chen, RE Ferner, ... American journal of medical genetics Part A 158 (1), 24-41, 2012 | 134 | 2012 |
| Genomic Profiling Reveals Alternative Genetic Pathways of Meningioma Malignant Progression Dependent on the Underlying NF2 Status S Goutagny, HW Yang, J Zucman-Rossi, J Chan, JM Dreyfuss, PJ Park, ... Clinical cancer research 16 (16), 4155-4164, 2010 | 130 | 2010 |
| The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2 ME Baser, L Kuramoto, R Woods, H Joe, JM Friedman, AJ Wallace, ... Journal of medical genetics 42 (7), 540-546, 2005 | 130 | 2005 |
| Correlations between genomic subgroup and clinical features in a cohort of more than 3000 meningiomas MW Youngblood, D Duran, JD Montejo, C Li, SB Omay, K Özduman, ... Journal of neurosurgery 133 (5), 1345-1354, 2019 | 125 | 2019 |
| Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas S Goutagny, E Raymond, M Esposito-Farese, S Trunet, C Mawrin, ... Journal of neuro-oncology 122, 313-320, 2015 | 113 | 2015 |
| Associations of meningioma molecular subgroup and tumor recurrence MW Youngblood, DF Miyagishima, L Jin, T Gupte, C Li, D Duran, ... Neuro-oncology 23 (5), 783-794, 2021 | 112 | 2021 |
| Everolimus and octreotide for patients with recurrent meningioma: results from the phase II CEVOREM trial T Graillon, M Sanson, C Campello, A Idbaih, M Peyre, H Peyrière, ... Clinical Cancer Research 26 (3), 552-557, 2020 | 111 | 2020 |
| Conservative management versus surgery for small vestibular schwannomas A Bozorg Grayeli, M Kalamarides, E Ferrary, D Bouccara, H El Gharem, ... Acta oto-laryngologica 125 (10), 1063-1068, 2005 | 108 | 2005 |
| Auditory brainstem implant in neurofibromatosis type 2 and non-neurofibromatosis type 2 patients AB Grayeli, M Kalamarides, D Bouccara, E Ambert-Dahan, O Sterkers Otology & Neurotology 29 (8), 1140-1146, 2008 | 107 | 2008 |
| Comparative pathology of nerve sheath tumors in mouse models and humans AO Stemmer-Rachamimov, DN Louis, GP Nielsen, CR Antonescu, ... Cancer research 64 (10), 3718-3724, 2004 | 100 | 2004 |
| SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas J Boetto, F Bielle, M Sanson, M Peyre, M Kalamarides Neuro-oncology 19 (3), 345-351, 2017 | 96 | 2017 |
| Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2 DG Evans, M Kalamarides, K Hunter-Schaedle, J Blakeley, J Allen, ... Clinical cancer research 15 (16), 5032-5039, 2009 | 93 | 2009 |
